Business Context and Reporting Period
This Form 8-K filing by 22nd Century Group, Inc. (Nasdaq: XXII) reports a significant executive leadership change. The report date is June 13, 2022, with the earliest event reported occurring on that date, though the appointment of the new CFO became effective on June 15, 2022.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and employment terms.
Material Changes
- Appointment of CFO: R. Hugh Kinsman was appointed Chief Financial Officer, effective June 15, 2022. He previously served as CFO of GVB Biopharma, a newly acquired wholly-owned subsidiary of the Company.
- Departure of Former CFO: Richard Fitzgerald was permanently separated from the Company on June 13, 2022, in connection with the hiring of Mr. Kinsman.
- Compensation Structure: Mr. Kinsman entered into a three-year employment agreement with an initial base salary of $290,000. He is eligible for cash bonuses and performance units based on targets set by the Company.
- Severance Terms: If terminated without Cause, Mr. Kinsman is entitled to 12 months of base salary continuation plus health care coverage.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of material risks and contingencies beyond the standard disclosure regarding the executive transition. No unusual items were reported.
Investor Verification Checklist
- Verify the integration of GVB Biopharma into 22nd Century Group's operations following the acquisition.
- Review the specific performance targets for Mr. Kinsman's bonus and performance unit awards, which are not detailed in this filing.
- Confirm the status of the Company's financial reporting following the departure of the former CFO.
- Check for any subsequent filings regarding the transition of duties between the former and new CFO.